DEFA14A: Dogwood Therapeutics Q4 2025 Update: Neuropathy Treatments

Dogwood Therapeutics, Inc. provides a Q4 2025 update, detailing its deep commitment to advancing first-in-class therapeutic treatments for cancer patients suffering from neuropathy.

Summary

• Dogwood Therapeutics (DWTX) posted a Q4 2025 investor presentation on its website, outlining its strategic focus and pipeline progress.
• The company is dedicated to developing first-in-class therapeutic treatments for cancer patients suffering from neuropathy, with a long-term goal to expand into general cancer pain and acute surgical pain.
• The presentation highlights two primary research programs: Halneuron, a Nav1.7 channel blocker, and SP16, an LRP1-agonist.
• Halneuron is currently in Phase 2b development for Chemotherapy-Induced Peripheral Neuropathy (CINP), with over 80 patients randomized and 60 having completed treatment in the ongoing 4-week study.
• Previous Phase 2 Cancer Related Pain (CRP) study data for Halneuron demonstrated statistically significant efficacy, with 51% of patients experiencing a 30% reduction in pain compared to 35% on placebo.
• SP16 is in early clinical stage development for CIPN, with its Phase 1b safety study fully funded by the National Cancer Institute (NCI).
• Upon shareholder approval for the conversion of existing preferred stock, the company anticipates approximately 30 million common shares on a fully diluted basis.
• Post-conversion, CK Life Sciences Intl. (Holdings) Inc. (CKLS) and Serpin Pharma, Inc. are expected to collectively own approximately 90% of DWTX common stock.
• The company targets a significant market opportunity, estimating ~$1.9 billion for CINP, ~$6 billion for the broader cancer pain market, and ~$35 billion for the global pain management drug market.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook on the company's drug development pipeline, highlighting statistically significant efficacy in previous trials, acceptable safety profiles, and a clear path forward with defined milestones. The NCI funding for SP16 is a strong positive. However, the company is still in clinical stages, and the high concentration of ownership post-conversion could be a factor for some investors. The overall tone is optimistic about future potential and market opportunity.

Positives

• Halneuron demonstrated statistically significant pain reduction in a Phase 2 CRP study, with 51% of patients achieving a 30% reduction in pain versus 35% on placebo (p-value 0.046).
• Halneuron responders in the Phase 2 CRP study experienced a long duration of pain relief, averaging 57.7 days post-injection.
• Halneuron has shown an acceptable safety profile in both CRP and CINP patients, with most adverse events being mild to moderate and resolving naturally within hours.
• The SP16 program is fully funded by the NCI through its next clinical milestone, providing external validation and financial support.
• Preclinical research for SP16 demonstrates analgesic effects and potential to prevent/repair nerve damage without interfering with common chemotherapy regimes.
• The executive team possesses extensive drug development and commercialization experience, enhancing confidence in pipeline execution.
• Halneuron exhibits selectivity for the Nav 1.7 channel in peripheral tissues, with low affinity for cardiac sodium channels and no blood-brain barrier crossing, minimizing central nervous system adverse events.
• A new synthetic API for Halneuron is targeted for CoM Filing in Q4 2025, with potential IP extension to 2045+.

Negatives

• The company's primary drug candidates are still in clinical development stages, with no commercialized products to date.
• There is significant shareholder concentration anticipated post-conversion, with CKLS and Serpin Pharma expected to own approximately 90% of DWTX stock.
• The "Important Additional Information" section highlights substantial risks and uncertainties related to forward-looking statements and the outcomes of clinical studies.
• The high reliance on opioids (38%-58% of CINP treatment) indicates a challenging competitive landscape and entrenched treatment paradigms for pain management.

Risks

• Substantial risks and uncertainties are associated with forward-looking statements, including the completion, timing, and results of current and future clinical studies for product candidates.
• Certain forward-looking statements are based on assumptions about future events that may not prove to be accurate.
• Market, industry, and third-party data presented have not been independently verified, and their accuracy or completeness cannot be guaranteed.
• Estimates and internal forecasts involve inherent risks and uncertainties and are subject to change based on various factors.
• The company's ability to obtain stockholder approval for the conversion of preferred stock and other matters related to the business combination with Wex Pharmaceuticals, Inc. is crucial.
• Cancer patients using opioids for pain management face risks of developing clinically significant adverse effects, including cognitive impairment, hallucinations, constipation, and nausea/vomiting.
• The broader societal issue of opioid addiction and abuse, with over 53,000 opioid deaths in the past 12 months in the US alone, highlights the challenges in pain management.

Future Outlook

The company anticipates significant milestones in Q4 2025, including filing new synthetic Halneuron IP, an interim data readout for the Phase 2b CINP study, and filing an IND for SP16. Patient enrollment for the SP16 Phase 1b study is projected for 1H 2026, with final data for the Halneuron Phase 2b study expected in Q2/Q3 2026. The company aims to expand Halneuron's utility to general cancer pain and post-surgical pain, and SP16 may synergistically complement Halneuron in treating pain post-chemotherapy, targeting a combined ~$5 billion cancer pain market.

Management Comments

• Dogwood is led by an executive team with extensive drug development and commercialization experience.
• Halneuron is a logical approach that we believe fulfills many requirements of an ideal analgesic.
• Halneuron is potentially best for treating established CINP pain.
• SP16 is potentially best for attenuation of CIPN during chemo.
• SP16 may enable neuroprotection, may preserve full chemo regimen and potential to synergistically complement Halneuron in treating pain post chemotherapy.

Industry Context

The company operates in the significant and growing pain management market, particularly focusing on cancer-related pain and chemotherapy-induced peripheral neuropathy (CINP). This area represents a major unmet medical need, with a substantial portion of patients currently relying on opioids, which carry significant risks of addiction and adverse effects. Dogwood's approach with Halneuron (a Nav1.7 channel blocker) and SP16 (an LRP1-agonist) aims to offer non-opioid alternatives, positioning it within a broader industry trend towards safer and more targeted pain therapies. The projected increase in chemotherapy utilization by 54% by 2040 underscores the expanding patient population for CINP treatments.

Comparison to Industry Standards

• Halneuron's efficacy in preclinical paw withdrawal models compares favorably with recently approved Suzetrigine at all tested doses, suggesting competitive potential in the analgesic market.
• Halneuron's mechanism of Nav 1.7 inhibition is supported by real-world patient experience, aligning with a targeted approach to pain management that seeks to minimize systemic side effects.
• The company's focus on non-opioid treatments for CINP directly addresses a critical gap, as opioids currently account for 38%-58% of CINP treatment, despite their severe side effects and addiction risks, which is a significant concern across the pharmaceutical industry.
• The NCI-funded SP16 research plan indicates external validation and support for its potential, a positive signal in the competitive drug development landscape for novel pain therapies.

Corporate Governance

Related Party Transactions

• CK Life Sciences Intl. (Holdings) Inc. (CKLS) owns ~2,108 shares of Series A and ~284 shares of Series A-1 Preferred Stock, which will convert into common stock upon shareholder approval.
• Serpin Pharma, Inc. (Serpin Pharma) owns ~179 Series A-2 Preferred Stock, which will convert into common stock upon shareholder approval.
• Post-conversion, CKLS and Serpin Pharma will collectively own approximately 90% of DWTX stock, indicating significant influence by these entities.

Stakeholder Impact

• Shareholders: Potential for dilution from preferred stock conversion, but also a clearer capital structure. The high concentration of ownership by CKLS and Serpin Pharma could impact minority shareholder influence.
• Patients: Potential for new, non-opioid therapeutic treatments for cancer-related neuropathy (CINP), addressing a significant unmet medical need and improving quality of life.
• Employees: Continued employment and potential growth opportunities as drug development progresses.
• Collaborators/Vendors: Ongoing and potential future collaborations related to drug development and manufacturing.
• Regulatory Authorities: Engagement with the FDA for IND filings and Fast Track Designation, ensuring compliance and progression of clinical programs.

Next Steps

• Target CoM Filing for new synthetic Halneuron API in Q4 2025.
• Dr. Gendreau to present Halneuron Program Overview at the 19th Annual Pain Summit, San Diego, CA on October 14, 2025.
• Recruitment of 100 patients in the Halneuron Phase 2b study in Q4 2025.
• New Synthetic Halneuron IP to be filed in Q4 2025.
• Phase 2b Interim Data Readout for Halneuron in Q4 2025.
• SP16 IND filed to advance to Phase 1b Safety Study in Q4 2025.
• Patient enrollment in SP16 Phase 1b CIPN Study in 1H 2026 (subject to FDA review).
• Final data for the 200-patient Halneuron Phase 2b CINP study in Q2/Q3 2026.
• Seek stockholder approval for conversion of preferred stock and other matters related to the business combination with Wex Pharmaceuticals, Inc.

Key Dates

Recommendation

The company presents promising preclinical and Phase 2 data for Halneuron, addressing a significant unmet medical need in CINP with a non-opioid approach. The NCI funding for SP16 is a strong positive. However, both programs are still in clinical development, and commercialization is years away. The high concentration of ownership post-conversion could limit liquidity and influence for new investors. While the long-term potential is attractive, the current stage of development and inherent risks of clinical trials suggest a 'hold' position, awaiting further positive clinical data and clarity on the path to market.

Keywords

Dogwood Therapeutics, DWTX, Neuropathy, Cancer Pain, CINP, Chemotherapy-Induced Peripheral Neuropathy, Halneuron, Tetrodotoxin, TTX, Nav1.7, SP16, LRP1 agonist, Pain Management, Clinical Trials, Biotechnology, Pharmaceuticals, Oncology, Drug Development, SEC Filing